arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences, Telecoms, Media and Technology

FT Digital Health Summit Europe 2018

From Fragmentation to Integration

Berlin |
Speakers include:
Gottfried Ludewig

Gottfried Ludewig

Federal Ministry of Health

Peter Gocke

Peter Gocke

Charité University Medical Center

Eve Roodhouse

Eve Roodhouse

NHS Digital

Overview

The latest instalment of the FT’s Digital Health Summit Europe will be held in Berlin and will home in on the approaches, investment and frameworks needed to implement connected health solutions. Health leaders will share their experiences and vision for delivering digitally-driven integrated care.

fallback
fallback Add to my Calendar 06/19/2018 08:00:0006/19/2018 18:00:00trueFT Digital Health Summit Europe 2018The latest instalment of the FT’s Digital Health Summit Europe will be held in Berlin and will home in on the approaches, investment and frameworks needed to implement connected health solutions. Health leaders will share their experiences and vision for delivering digitally-driven integrated care.FT-Digital-Health-Summit-Europe-201887d82e0716f9479f28ac4c5f7bd1d3a8MM/DD/YYYY

Untitled Block

All sessions will be delivered in English, unless otherwise stated.

fallback

Executive Summary

EVENT BROCHURE Digital Health

Download now

Event Brochure

To download the event brochure please fill in the form below. All fields are required

Please complete all the highlighted fields

Form submission failed. Please retry.

For more information about how we use your data please refer to our privacy and cookie policies.

Invites and offers from the FT

Receive exclusive personalised events invitations, carefully-curated offers, future speaking engagements and promotions from Financial Times Live

Thank you for submitting your details. Please download the event brochure.

2017 Testimonials

"Excellent speakers and well organised. I will definitely come again.” Nick Hirst, CIO, NIHR CRNCC

 “Excellent 1-day snapshot of the key issues in digital health.” Ed Currie, Smart Health Ambassador, TM Forum

 “Thanks a lot for the opportunity to be a part of this extraordinary event. It really has been a pleasure. Looking forward to see you again in the future”  Karl Pall, Director, Google

 “Excellent platform to have an open, frank discussion in an environment that is so traditional and fixated, yet cutting-edge in so many ways.” Khilona Radia, CEO, Antrum Biotech

 “High quality speakers” Lars Dahle, CEO, Dignio

fallback

Full Overview

Fragmentation in healthcare and the lack of coordination between departments and services are major barriers to be overcome as the transformation of health gathers pace across Europe. Digital technologies have the power to connect and integrate isolated and disparate services and deliver more intuitive and coordinated patient experiences.  However, with the huge number of new technologies, devices and applications, and growing amounts of data, there is the risk that digital innovations will add to the fragmentation if the issues of interconnectivity, security and access are not addressed.

The keynotes, interviews, panels and debates will explore how technology can help to unite the fragments, strengthen systems, and improve patient experiences and outcomes throughout the continent.  

fallback

Speakers (26)

Gottfried Ludewig

Gottfried Ludewig

Head of Directorate General of Digitalisation and Innovation
Federal Ministry of Health

Gottfried Ludewig is the Head of the Directorate General of Digitalisation and Innovation at the German Federal Ministry of Health, formed in April 2018. Previously, Dr Ludewig was a member of the Berlin House of Representatives and Vice Chairman of the CDU Parliamentary Group (2011-2018). In the last position, his focus was especially dedicated to strengthen the areas of research and innovation in the German healthcare sector. Dr Ludewig studied Economics at Berlin Technical University, where he also graduated with his Doctoral thesis on the Regulatory Framework of the German Health Insurance Sector. He has worked as Senior Consultant for Pricewaterhouse Coopers and was Federal Chairperson of the German Association of Christian Democrat Students (RCDS) from 2008 to 2010.

Peter Gocke

Peter Gocke

Chief Digital Officer
Charité University Medical Center

In April 2017 Peter Gocke was appointed as the first Chief Digital Officer (CDO) in the healthcare provider space in Germany. In this role, he is responsible for the digital transformation of the Charité, the academic hospital in Berlin, which is the largest AMC in Germany. Previously, Dr Gocke was the Director of IT (CIO) & process management (CPO) at Amedes AG, a large laboratory service provider and prior to that he was the CIO of the Academic Medical Center in Hamburg. In his former CIO position in Hamburg, he was in charge of several digitalization projects, which led to a first HIMSS EMRAM stage 7 award for a European hospital. He is a trained radiologist holding previous roles as Associate Professor of Radiology.

Eve Roodhouse

Eve Roodhouse

Director for Implementation and the Digital Environment
NHS Digital

Eve Roodhouse is Interim Director for Implementation and the Digital Environment at NHS Digital and Chair of the NHS Digital Women’s Network. She is passionate about supporting the NHS and Local Authorities to make the most of digital products and services and working with colleagues across the organisation to ensure NHS Digital becomes more responsive to its customers. Ms Roodhouse established the new Implementation and Business Change function in April 2017 which remains part of her portfolio and takes the lead on Digital Skills. She has more than 17 years of experience working in complex delivery environments (14 being in NHS informatics), with a breadth of experience that takes in all aspects of the programme management lifecycle from stakeholder engagement, business case development, procurement and supplier management, to software development, change management and managed closure.

Ms Roodhouse graduated from the Major Project Leadership Academy in February 2016. She started her career as a management consultant at Deloitte where she worked at Transport for London on the successful delivery of the London congestion charging scheme.

Xavier Prats Monné

Xavier Prats Monné

Director-General for Health and Food Safety
European Commission

Xavier Prats Monné has been the Director-General for Health and Food Safety of the European Commission since September 2015. He is responsible for EU policies and programmes in health and food safety, including the promotion of public health, the assessment of national healthcare systems' performance, pharmaceutical legislation, animal health and welfare, as well as the strengthening of Europe's capacity to deal with crisis situations in human health and the food sector. He previously served as Director-General for education and culture and as Director for employment policy.

He holds degrees in Social Anthropology from the Universidad Complutense (Madrid, Spain); in Development Cooperation from the International Centre for Advanced Mediterranean Agronomic Studies (CIHEAM; Paris, France); and in European Studies from the College of Europe (Bruges, Belgium), where he graduated first of the Class of 1981-82 and served as assistant professor.

Steve Papermaster

Steve Papermaster

Chairman and CEO
Nano Vision

Steve Papermaster is the founder, chairman and CEO of Nano Vision, a company dedicated to dramatically accelerating the development of cures for a vast range of cancers, infectious diseases and health conditions. The Nano platform includes the Nano Sense™ chip, the molecular data blockchain, the Nano Cure Coin and therapeutic cure developments.

Mr Papermaster was appointed and served two terms as a senior advisor to former US President George W Bush regarding domestic and global strategy for innovation, technology, healthcare and science. He was a member and co-chair of the President's Council of Advisors for Science and Technology (PCAST). As a presidential advisor, he helped lead the National Nanotechnology Initiative, the Human Genome Project and the White House Fellow, one of America’s most prestigious programs for leadership and public service. He also served as secretary of the Energy Advisory Board and National Labs.

Mr Papermaster is highly experienced in founding, growing, funding, acquiring, and investing in innovative technology companies around the world. His leadership titles include founder, chairman, CEO, and board member for several publicly traded and private companies, including: LabNow, Moxie, Medaphis, Powershift Group, ROME Corp (acquired by TriplePoint Technologies), TechRepublic (acquired by CNET Networks), Perficient, Vignette Corp, Per Se Technologies, Tipping Point Technologies, Novell and BSG Corp.

Mr Papermaster co-authored the book “Smart Life,” which is a guide to technology innovation that drives major social changes around the world. He graduated from the University of Texas at Austin School of Business with highest honors.

Penelope Dash

Penelope Dash

Senior Partner
McKinsey & Company

Penny Dash leads McKinsey’s healthcare work across Europe with a focus on redesigning services to improve quality and efficiency of care delivery. Ms Dash has over 20 years’ experience in health care consulting and also spent time as Head of Strategy for the NHS. From 2004 to 2006 she was a non-executive Director of Monitor, the Independent Regulator for Hospitals in England and served as a Trustee and Vice Chairman of the King’s Fund from 2006 to 2014.

Ms Dash originally trained as a doctor in Cambridge and London and is a Fellow of the Royal College of Physicians of London. She has an MSc in Public Health Medicine and a MBA from Stanford Business School where she was a Fulbright Scholar.

Marie McCarthy

Marie McCarthy

Senior Director Product Innovation
ICON

Marie McCarthy is part of the multidisciplinary Innovation Team at ICON plc.  Seen as a key Intrapreneur within the organisation she has specific responsibility for developing solutions in the direct to patient paradigm. Her focus is primarily on the use of wearables and sensors in clinical trials, with particular emphasis on the potential these devices have to monitor the physical behaviours of the digital patient.  Ms McCarthy has a background in scientific research and has worked in a number of industries including IVD and Medical Devices.  She is a published author and spoken at a number international conferences.   She acts in an advisory capacity for a number of sponsors on the relevant clinical endpoints and considerations to be deployed when embarking on the incorporation of wearable technology into clinical trials. As part of the ICON CNS innovation group she provides insight into outcomes addressed by wearable technology.  Within the Innovation team she has been directly responsible for the running of a number of proof-of-concepts including a number of multi-sensor studies.  She has written and contributed to numerous articles focusing on use many of which are on the use of wearables in clinical trials. 

Chen Admati

Chen Admati

Head of Intel® Pharma Analytics Platform
Intel

Chen Admati is the head of Intel® Pharma Analytics Platform at Intel. Intel® Pharma Analytics Platform is an edge-to-cloud artificial intelligence platform for remote monitoring of patients during clinical trials using wearable and sensors. Using big data and machine learning techniques, the platform enables to quantify the impact of therapies, promise to transform research and drug development in various chronic diseases. Prior to leading Intel® Pharma Analytics Platform, Ms Admati managed various artificial intelligence solutions and services in various domains. She is AI professional, brings vast of understanding in the healthcare domain, and how to successfully digitize clinical trials.

Alberto Tozzi

Alberto Tozzi

Chief Innovation Officer
Bambino Gesù Children's Hospital

Alberto Tozzi is a pediatrician and an epidemiologist with experience in vaccines and epidemiology of transmissible diseases. He has worked as a researcher with the Italian National Health Institute for more than 15 years, participating and coordinating several projects concerning the prevention and surveillance of infectious diseases. In 2004 Dr Tozzi moved to the Bambino Gesù Children’s Hospital, where he continued to work in vaccine preventable diseases and started developing projects on eHealth and digital medicine. Dr Tozzi is serves the Bambino Gesù Children’s Hospital as Chief Innovation Officer and is head of the Multifactorial and Complex Diseases Research Area. He is responsible for the development of telemedicine programmes within the Hospital. Among the others, he followed a project on pattern of contacts in a pediatric ward measured through wearable RFID tags explaining the diffusion of infectious diseases, and studies on the prediction of influenza and rhinoconjunctivitis through Twitter analysis. He represents the Bambino Gesù Children’s Hospital in the International Society for Pediatric Innovation. He also collaborates with the WHO Vaccine Safety Network for a programme on data driven communication.

John  Moore

John Moore

Director, Customer Lab
Bupa

John Moore began his career putting Australia’s Northern Territory on the tourist map before joining the National Australia Bank. It was there the trained economist discovered his talent for using data to solve customer’s problems, going on to transform the brand and customer experiences of Canada’s Scotiabank and CIBC, telecoms giant Vodafone, and Australian businesses, Suncorp and Australia Post. These days, Mr Moore is focused on finding ways of helping Bupa's customers live longer, healthier, happier lives.

David Liverseidge

David Liverseidge

Chief Information Officer
Nuffield Health

David Liverseidge took up the position of Chief Information Officer in January 2017. Prior to this he had been leading the organisation’s business technology agenda in the Hospitals area, initiating a programme of work now in flight to deliver an integrated Electronic Health record for the organisation. He is passionate about the application of technology to improve customer experience, transform the way the business operates and improve the lives of Nuffield Health’s customers, members, patients and partners. Mr Liverseidge’s previous experience covers a variety of industries where he has held a variety of UK and international technology related leadership roles at organisations such as AstraZeneca and Sony Corporation. He started his career in IT consulting with Price Waterhouse.

Jyothis George

Jyothis George

Global Head of Clinical Development (CardioMetabolism),
Boehringer Ingelheim

Jyothis George is a physician-scientist with a decade of clinical research and development of expertise involving over 40,000 patients from more than 40 countries.  He currently leads Boehringer Ingelheim’s clinical development team in CardioMetabolism, which includes two blockbuster drugs.In addition to roles in academia, hospitals and pharmaceutical industry, Dr George has the experience of running a medical informatics company focusing on digital applications in medicine. Tackling inefficiencies in clinical trials using digital and other innovations is therefore a natural interest.  He is a regular contributor to think tanks drawing together thought leaders from academia, industry and regulatory backgrounds.Leveraging this spectrum of experience, Dr Jyothis lead the team to design a lean global clinical trial programme  in chronic kidney disease, with world-leading university partners (Oxford and Duke). This programme incorporates innovative approaches to streamline clinical trial conduct. Within Boehringer Ingelheim, he serves on the global steering committee overseeing the integration of digital tools into medicine.

Carina Namih

Carina Namih

Partner
Episode 1

Carina Namih is a Partner at Episode1 Ventures, where she invests across the latest trends in: health technology, computational biology, AI, VR, blockchain and robotics. Ms Namih spent 5 years in Silicon Valley, where she founded HelixNano with a team from MIT – applying AI to genetic data. She is an alumnus of YCombinator, Singularity University and Oxford University. She sits on the curatorial committee of the ScienceGallery in London. Previously, Ms Namih was an Entrepreneur-in-Residence at Johnson&Johnson Innovation and an M&A advisor with Goldman Sachs. 

Felicitas Riedl

Felicitas Riedl

Head of Life Sciences Division
European Investment Bank

Felicitas Riedl is the Head of the Life Sciences Division at the European Investment Bank in Luxembourg, responsible for the life sciences, health and pharmaceutical sectors in the Projects Directorate of the Bank. Prior to this, Ms Riedl was a Life Sciences Specialist in the same division. Previously, she worked at the European Investment Fund as an Investment Manager with a particular focus on technology transfer. Her main tasks there were the analysis of technology transfer, the development of financial vehicles targeting this particular area and the implementation of these funding structures.

Prior to that, Ms Riedl worked as a strategy consultant for L.E.K. Consulting in Munich and Los Angeles. There, she focused on Private Equity / M&A and Life Sciences. Her work included business planning, market research, development of market entry strategies as well as financial and commercial due diligences.

She earned a Master of Science from the Philipps University of Marburg and Stanford University in Palo Alto with a major in human genetics and molecular biology.

Sohini Chowdhury

Sohini Chowdhury

Deputy CEO
The Michael J Fox Foundation for Parkinson's Research

Sohini Chowdhury joined The Michael J Fox Foundation in 2005. As Deputy CEO, she oversees the Research Partnerships team and works closely with the Foundation's executive leadership and Board of Directors in building the organization’s capacity as an unprecedented stakeholder in drug development — a nimble, resourceful, patient-focused problem-solver whose efforts are demonstrably accelerating progress toward treatment breakthroughs and a cure. Ms Chowdhury  was elevated to the role of Deputy CEO in 2017. In her previous capacity as SVP, Research Partnerships at the Foundation, she established and led the formal industry strategy, building ongoing relationships with pharmaceutical firms and biotechs as research partners and as sponsors of the Foundation’s scientific and educational programs. She has led development of programs critical to increasing patient engagement in Parkinson’s research including the Fox Trial Finder smart-match tool and Fox Insight.  Ms Chowdhury also is responsible for administrative and operational oversight of the MJFF-sponsored landmark clinical study PPMI, or the Parkinson’s Progression Markers Initiative, launched by MJFF in 2010 to identify and validate Parkinson’s biomarkers. Prior to joining MJFF, she worked at the World Economic Forum for five years. As the Senior Community Manager of the Forum's Technology Pioneers program, she was responsible for annually selecting and integrating innovative biotech, energy and IT technology companies into Forum activities.  She also worked directly for the Forum's CEO, acting as his liaison with key Forum stakeholders and overseeing several in-house projects.  Ms Chowdhury graduated with an MA from Georgetown University, and holds a BA in International Studies from Vassar College.

Henk de Jong

Henk de Jong

Chief of International Markets
Philips

Henk de Jong was appointed Chief of International Markets in April 2017 with responsibility for results of customer-facing activities across the world (with the exception of North America and Greater China). He is also a member of the Board of Philips Capital N.V.  Mr de Jong joined Philips in 1990. His most recent role was Market Leader in Latin America. He also led major transformations in businesses across the region. Among his achievements, he drove productivity implementing LEAN; led a more a customer-centered approach in the Personal Health businesses and oversaw shift towards a more innovative solutions-based approach in the Health Systems businesses. Prior to that he held a number of leadership roles in Philips’ former Consumer Lifestyle businesses in Europe and Asia.

He holds an MBA from the Rijksuniversiteit Groningen and graduated in Finance for Senior Executives at Harvard Business School. He has also taught transformation management at ISE business school in São Paulo.

Mathias Goyen

Mathias Goyen

Chief Medical Officer, Europe
GE Healthcare

Mathias Goyen is responsible for leading GE Healthcare’s medical, clinical and evidence generation strategies for product modalities in Europe. Together with his team he provides leadership in healthcare economics and outcomes research and comparative effectiveness research to develop customer value propositions for new and existing products.

Dr Goyen began his career as a diagnostic Radiologist working at Essen and Hamburg, Germany. He was appointed Professor of Diagnostic Radiology at the University of Hamburg in 2010. His previous experience also includes 5 years as Managing Director of UKE Consult and Management GmbH, a subsidiary of the University Medical Center Hamburg, where he was responsible for the overall consulting and foreign business of the University Medical Center Hamburg. Together with the leadership team of the hospital Dr Goyen established a Comprehensive Cancer Center linking clinical medicine with new oncologic research strategies. He holds a medical degree from the University of Bochum, Germany.

Erwin  Böttinger

Erwin Böttinger

Head, Digital Health Center, Professor for Digital Health and Personalized Medicine,
Hasso-Plattner Institute

Erwin Böttinger is Professor for Digital Health - Personalized Medicine and Head of Digital Health Center at the Digital Engineering Faculty of the Hasso Plattner Institute (HPI) GmbH at the University of Potsdam. He is the founding director of the HPI Digital Health Center. From November 2015 to July 2017 Prof Dr Böttinger was the CEO of the Berlin Institute of Health (BIH). Prof Dr Böttinger is considered an international expert in personalized medicine and digital health, in particular for his performance as founding director of the Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai in New York, USA, from 2005 to 2015.

Teemupekka  Virtanen

Teemupekka Virtanen

Senior Adviser, National eHealth Services
Ministry of Social Affairs and Health, Finland

Teemupekka Virtanen has worked at the Ministry of Social Affairs and Health for over 10 years. During this time he has been the Chief Security Officer of the national eHealth systems, head of the national eHealth projects and currently he is leading the project building new generation eHealth services for citizens. Dr Virtanen’s background is in electronics and computers, he has an MBA in security management and is also a qualified secondary school teacher.

Dr Virtanen has worked in a variety of roles. He was the Information Security Manager in the Prime Minister’s office, where he was also building new generation Internet services. He has served as the Chief Information Security Officer of the Finnish Defence Forces and was also the Chief of Security at Alma Media, the biggest national media company where he developed the organisation’s Internet based media. Previously he was Professor of Security and Internet-based systems at Aalto University. His current role involves changing the way of thinking in social- and healthcare.

Mitchell Silva

Mitchell Silva

Patient Advocate

Mitchell is a patient advocate with a long term condition. Based on his experience as a patient in combination with his experience as a researcher, he started to develop tools to follow his condition over time. Mitchell is also co-founder of Esperity, a platform to encourage patients to find peer support, find clinical trials and to promote self-tracking. He participates in and organising patient partnership programs aiming at including patient input during the design phase of new services for patients. Mitchell is also the chair of the Belgian EUPATI national platform and a board member of ReumaNet. He has a PhD in bio-engineering from the KULeuven. 

Christian Lautner

Christian Lautner

Co-founder and Managing Partner
Flying Health

Christian Lautner is Co-founder and Managing Partner at Flying Health, focusing on serious digital health technologies i.e. digital biomarkers and digital therapies.

Previously, he co-founded one of the first German doctors rating platform imedo.de and later joined qualitaetskliniken.de as CEO to work towards comparability of hospital quality accessible for everyone via digital devices.

Diana Heinrichs

Diana Heinrichs

CEO and Co-founder
Lindera

Diana Heinrichs, CEO and Co-founder of Berlin-based Lindera, has developed the first data science tool for the point of care. Her experience at Microsoft Deutschland on the future of the digital world of work helped her to frame the question – how can older people live longer and independently at home?

Virgilio Bento

Virgilio Bento

Founder and CEO
Sword Health

Virgilio Bento founded SWORD Health in 2014, while undergoing his PhD in electrical engineering. Each year, more than 230 million people require physical rehabilitation for common musculoskeletal disorders alone, and ageing populations worldwide are only expected to exacerbate this problem. Recognising that the demand for rehabilitation vastly outweighed supply, and fuelled by his own experiences following his brother’s accident and rehabilitation at the CIREN centre in Cuba, Dr Bento realised that technology and data sharing offered a solution that kept the personal relationship intact. SWORD Health’s flagship product, SWORD Phoenix, is an AI-powered digital physiotherapist that grants patients access to high-intensity physiotherapy from the comfort of their homes. Through SWORD Phoenix, patients have access to intensive, task-specific rehabilitation protocols at home, ultimately ensuring better patient outcomes. Clinical trials have found that 93% of patients demonstrated improvement in the quality of motor tasks when using the platform. SWORD Health is currently operating in the USA, Canada, Australia, Norway and Portugal, and has raised $6 million in funding so far. In addition to his work for SWORD, Dr Bento holds multiple patents, has co-authored more than 40 research papers, and has founded several start-ups from his home city of Porto, Portugal.

Claudio Hasler

Claudio Hasler

Co-founder and CEO
PeakProfiling

Claudio Hasler is Co-founder and CEO of PeakProfiling - a pioneer in speech sound analysis. Based on more than 20 years of research, the company is able to detect mental and physical disorders from the sound of the human voice. Previously, Mr Hasler was leading the Business Intelligence and Analytics departments as well as all digital activities of one of the largest German OTC players. Moreover, he has been working for Google in various roles, e.g. as Industry Manager.

Alex Gilbert

Alex Gilbert

Partnerships and Talent
Medopad

Alex Gilbert leads Talent and manages Pharmaceutical Partnerships at Medopad, one of the world’s highest-growth digital health companies. He has been working within the Digital Health industry for the past 4 years alongside healthcare, pharmaceutical and tech organisations, assisting them in both internal as well as external growth. Having joined as Medopad employee #8, he has seen the business grow over 400%, raising over $28M in the process. Through his experience at Medopad, he has signed national projects with governmental bodies, further defined Medopad’s commercial proposition, and lead on many of the companies most strategic hires. Mr Gilbert’s foremost passion is the simplification of digital health in order to empower patients to take control of their care.

Morten Remmer

Morten Remmer

Chief Growth Officer
LEO Innovation Lab

Morten Remmer is Chief Growth Officer at LEO Innovation Lab, an independent unit of LEO Pharma established to meet patient needs through digital innovation. Since joining the unit in 2016, Mr Remmer has instilled an agile development ideology that is driven first and foremost by the patient perspective. From face-to-face user tests to qualitative insights collected on a global scale, he has overseen the growth of several disruptive healthtech solutions; from offering AI-assisted diagnostic insights, to the digitisation of clinical trial recruitment.

fallback

CO-CHAIRS (2)

Sarah  Neville

Sarah Neville

Global Pharmaceuticals Editor
Financial Times

Sarah Neville began her career on local and regional newspapers, eventually becoming political editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post. She joined the Financial Times in 2001 and has since held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and public policy editor in 2011. She was appointed Pharmaceuticals Correspondent in 2016.

David  Crow

David Crow

Senior US Business Correspondent
Financial Times

David Crow is a Senior US Business Correspondent for the Financial Times, covering telecoms, technology, and pharmaceuticals. He is based in New York. He previously worked on the FT's main news desk in London, where he edited the front page of the print edition. Before joining the FT he was Managing Editor of City AM, the London financial newspaper.

Mr Crow has an MA in English Literature from the University of Glasgow.

Agenda - 19th Jun

  • 8:00am
    Registration and networking
  • 8:50am
    Chair’s opening remarks

    Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 9:00am
    Opening address: Digital Health in Europe – creating opportunities for our health systems

    Gottfried Ludewig, Head of Directorate General of Digitalisation and Innovation, Federal Ministry of Health

  • 9:20am
    Health leaders’ panel: Perspectives on integrated healthcare delivery

    Healthcare services across Europe are facing challenges around cost, security, engagement and integration. During this opening panel, European health leaders will share perspectives on overcoming vulnerabilities and discuss best practices for realising a smooth transition to ‘mainstream’ digital health.

    • Ways of creating smarter systems that are useful, usable and used. How far, how fast and at what scale can the transition to digital health be made?
    • What are the difficulties of combining technologies from different providers into one integrated healthcare experience for the patient?
    • How is the digital transition being paid for?
    • How can healthcare professionals keep up with the new wave of technological innovation?
    • Initiatives to equip the workforce with skills, knowledge and experience

    Keynote:  Eve Roodhouse, Director for Implementation and the Digital Environment, NHS Digital

    Panel:  

    Peter Gocke, Chief Digital Officer, Charité University Medical Center

    Xavier Prats Monné, Director-General, Directorate-General for Health and Food Safety, European Commission

    Teemupekka Virtanen, Senior Adviser, National eHealth Services, Ministry of Social Affairs and Health, Finland

    Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 10:20am
    Keynote Interview

    Steve Papermaster,  Chairman and CEO, Nano Vision

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 10:40am
    Networking break
  • 11:00am
    Discussion Panel: Breaking down the data silos

    Historically, the fragmented nature of health systems in Europe has made it difficult to share information, and with more and more data sets being created in isolation, the proliferation of big data is adding to the fragmentation. This session will explore ways of tackling the integration challenges to ensure that the data acquired by doctors, hospitals, laboratories and technology companies is shared and exploited securely and for the benefit of the patient.

    • Who owns and controls the data and how can it be shared safely and flow freely across the health spectrum?
    • Building transparency and trust and the impact of changes in data protection legislation
    • Creating efficient digital pathways and getting data to where the decision making processes are taking place.
    • To what extent can the patient be put in control of their own information?
    • What can be learnt from other industries such as banking and retail about standardising and integrating data across platforms?

    Mathias Goyen, Chief Medical Officer, Europe, GE Healthcare

    David Liverseidge, Chief Information Officer, Nuffield Health

    Alberto Tozzi, Chief Innovation Officer, Bambino Gesù Children's Hospital

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 11:50am
    Investment Panel: Balancing risk and opportunity

    In the fast-evolving digital health landscape, the pressure is on for technology developers to differentiate themselves from the competition as they seek to attract investment capital. This session will consider the extent to which digital health is continuing to be fertile ground for investment and which opportunities are exciting investors in 2018.

    • Patterns of investment: which health-tech and digital products are showing the best ROI?
    • What are investors in tech-enabled health looking for?
    • The outlook for consolidation: M&A activity and impact.
    • What will investment look like post-Brexit?

    Christian Lautner, Co-founder and Managing Partner, Flying Health

    Carina Namih, Partner, Episode 1

    Felicitas Riedl, Head of Life Sciences Division, European Investment Bank

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 12:40pm
    Fireside chat: Delivering value-based care

    Penelope Dash, Senior Partner, McKinsey & Company 

    Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 1:00pm
    Lunch
  • 2:00pm
    Digital health dialogue: The human approach to disruption: integrating the voice of the patient

    High on the agenda is the need to build trust and engage patients in the transformation of healthcare. Understanding what the individual wants and integrating their voice into the development phase of digital technologies and services will help to deliver more intuitive experiences and enable patients to take control of their health, diagnosis and treatment. This dialogue will focus on how collaboration is driving acceptance and engagement and putting the person at the centre of personalised health.

    Erwin Böttinger, Head, Digital Health Center, Professor for Digital Health and Personalized Medicine, Hasso-Plattner Institute

    Morten Remmer, Chief Growth Officer, LEO Innovation Lab

    Henk de Jong, Chief of International Markets, Philips

    John Moore, Director, Customer Lab, Bupa

    Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 2:45pm
    Special focus:  The digital reinvention of clinical trials

    Digital technologies are starting to prove their worth in the quest to tackle costs and inefficiencies and streamline the clinical trial process. Social media, big data, wearables and mobile devices are transforming the collection and analysis of patient information. Going forward, how can clinical trials be further moved into the digital age?

    • In what ways are pharma companies adapting their R&D processes and accelerating progress towards digital drug discovery?
    • How can AI technologies, such as machine learning, be used to provide better insights, analysis and understanding of data?
    • How is regulation evolving and what barriers does it pose?
    • Could trials be conducted entirely using measurements taken with remote devices? What would this do to costs and patient engagement? And what would it mean for trial design?

    Chen Admati, Head of Intel® Pharma Analytics Platform, Intel

    Sohini Chowdhury, Deputy CEO, The Michael J Fox Foundation for Parkinson's Research

    Jyothis George, Global Head of Clinical Development (CardioMetabolism), Boehringer Ingelheim

    Marie McCarthy, Senior Director Product Innovation, ICON

    Mitchell Silva, Patient Advocate

    Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 3:30pm
    Networking break
  • 3:50pm
    Technology Spotlight: At the cutting edge of health transformation

    This series of brief presentations and quick-fire interviews will shine a spotlight on the innovators and trailblazers who are broadening the frontiers in prevention and treatment. Companies at the cutting edge of digital health will present what their technologies offer in terms of impact on patients and potential returns on investment and discuss their plans for market adoption and integration.

    Virgilio Bento, Founder and CEO, Sword Health

    Alex Gilbert, Partnerships and Talent, Medopad

    Claudio Hasler, Co-founder and CEO, PeakProfiling

    Diana Heinrichs, CEO and Co-founder, Lindera

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 4:55pm
    Closing remarks

    David Crow, Senior US Business Correspondent, Financial Times

  • 5:00pm
    Drinks reception

Why attend?

  • Assess how patients are being empowered and further involved in the transformation of healthcare
  • Hear how collaborations between pharma and big tech are enriching the commercial viability of digital health
  • Meet and greet with the full array of industry stakeholders, from healthcare to technology, pharma to start-ups, regulation to government
  • Identify solutions in overcoming cyber security threats in digital health
  • Don’t get left behind - be part of a must-attend event mapping the continued transformation of healthcare
fallback

Who attends?

FT Live has a reputation for delivering very senior board level audiences to attend a wide range of world class thought-leadership events across the globe for nearly 40 years. 

The FT Digital Health Summit Europe will be attended by: 

- Pharmaceutical and biotechnology companies 
- Healthcare Providers
- Medical Device manufacturers 
- Health insurers
- Investment banks 
- Hospital Management
- Clinicians 

fallback

Fees

Ticket Type

Fee

Early Bird Ticket (ends 20 March)

€899+VAT

Standard Summit Ticket

€999+VAT

fallback

Sponsorship Opportunities

  • Gain access to 150 Senior Executives from the Digital Health Industry, who will be attending the event;
  • Brand alignment with the FT and its unrivalled credibility;
  • Demonstrate thought leadership around the current critical issues affecting the healthcare industry;
  • Benefit from sustained international visibility through our advertising and marketing campaigns

Joe Hames

Commercial Manager, Global Industries

T: +44 (0)207 873 4551

M: +44 (0)791 329 2038

E: joe.hames@ft.com

fallback

Venue

Estrel Berlin
Sonnenallee 225
Berlin 12057

Germany

Tel: +49 30 68310

fallback

Presented By (1)

The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. In 2016 the FT passed a significant milestone in its digital transformation as digital and services revenues overtook print revenues for the first time. The FT has a combined paid print and digital circulation of more than 910,000 and makes 60% of revenues from its journalism.

Photos from 2017 FT Digital Health Summit Europe

Please click on this link to access photos from our 2017 summit. 

34767223474_ddf608165e_m

34767220674_5d6565ac36_m (1)

35440147582_bd57eaf664_m

fallback

Lead sponsors (3)

ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.

ICON’s award-winning study execution capabilities have led to the approval of 18 of the world’s top 20 best-selling drugs.

With headquarters in Dublin, Ireland, ICON currently, operates from 97 locations in 38 countries and has approximately 13,380 employees. For further information please visit www.iconplc.com  Follow @iconplc on Twitter.

Intel is a world leader in the design and manufacturing of essential products and technologies that power the cloud and an increasingly smart, connected world. Intel delivers computer, networking, and communications platforms. We are expanding the boundaries of technology through our relentless pursuit of Moore’s Law and computing breakthroughs that make amazing experiences possible. To learn more on our work in healthcare, visit intel.com/healthcare or follow us on Twitter @IntelHealth.

Knowledge Partner (1)

McKinsey & Company is one of the world’s leading management consulting firms. For over 90 years, we have helped our clients achieve substantial, lasting improvements in their performance, including in the healthcare sector. McKinsey brings a global 360° perspective across all stakeholders and an understanding of how healthcare really works.  We have the experience and scale to provide real expertise across the system.

Globally, our Pharmaceuticals & Medical Products  and Healthcare Systems & Services teams includes more than 1,700 consultants, over 150 doctors with patient care or research experience, and at least 250 consultants with Master’s or doctoral degrees in the life sciences and medical fields. In addition, to fully capture opportunities, we can draw on more than 1000 advanced analytics experts and data scientists, 250 world class innovators and designers and over 2300 digital consultants developers.

Associate Sponsor (1)

Digital transformation and continuous improvement are key priorities in Bupa’s strategic framework, which is why we set up our Customer Lab in 2017.

The Customer Lab is giving us a better understanding of our customers and what they really want so we can challenge the way we think, and give them new solutions using digital technology. But we can’t do it alone, which is why we’re partnering with startups and other businesses to explore ideas for more connected, intuitive healthcare experiences.

With the freedom to move fast and experiment, and the power of Bupa’s 78,000 people, together we'll discover new ways to help people live longer, healthier, happier lives.

www.bupa.customerlab.com

Exhibitor (1)

FarmaTrust is developing a fast, scalable, and secure blockchain solution that automates end-to-end tracking of medicinal products throughout the pharmaceutical supply chain. By harnessing the growing efficiency of big data, machine learning, blockchain technology and intelligent workflow processing, FarmaTrust both accurately and securely records data relating to serialised packages as they pass through each point in the supply chain lifecycle, in accordance with track and trace regulatory requirements.

The FarmaTrust Zoi system helps minimise the cost and resources required to comply with track and trace regulations. In addition, the FarmaTrust system integrates with existing enterprise software solutions, reducing the disruption to business operations and system changes in order to comply with track and trace reporting requirements. Ultimately, the FarmaTrust solution provides a cost-effective and comprehensive option for pharmaceutical companies, supply chain operators and retailers to verify and track genuine products across the lifecycle, down to the individual packet level. FarmaTrust’s Zoi platform not only has pharmaceutical companies as clients, but also includes Ministries of Health, governmental / regulatory bodies, NGOs and law enforcements as its customers. The end users get a free-to-use app.

Supporting Partner (2)

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

HealthManagement.org is a comprehensive print, digital and social media platform dedicated to promoting management, leadership, best practice and cross-collaboration in healthcare. With the active engagement from thought leaders and well-respected national and international associations, HealthManagement provides comprehensive information related to clinical practice, hospital administration, latest research, technology advances, major practice challenges and valuable management ti

Contact Us

Alexsandra Silva
Media Partner and Press Enquiries
Financial Times
Ailsa Matkevich
Speaking Opportunities
Financial Times
Joe Hames
Sponsorship Opportunities
Financial Times
Toby Barran
Delegate Booking and Registration Enquiries
Financial Times